BMS Buys IFM Therapeutics for Cancer Pipeline

Bristol-Myers Squibb announced the acquisition of IFM Therapeutics, a startup biotech focused on developing therapies that modulate novel targets in the immune system to treat cancer, autoimmunity and inflammatory disorders.

BMS will buy the privately held IFM for an upfront payment of $300 million, gaining access to the company's preclinical cancer programs.

Specifically, the acquisition will give BMS full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.

Several drugmakers are joining the growing group of protestors who are distancing themselves from the Fox News Channel shows featuring Tucker Carlson and Jeanine Pirro after the hosts were accused of making bigoted statements.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.